What type of study is this?

This is a Cohort Study study (also classified as: Pre-Registered Trial).

What question did this study set out to answer?

This study evaluates the effectiveness of a novel ultrasensitive ctDNA assay for detecting molecular residual disease in colorectal cancer patients.

View Full Paper

Ask AI

Bookmark

This study evaluates the effectiveness of a novel ultrasensitive ctDNA assay for detecting molecular residual disease in colorectal cancer patients.
Evaluated patients with stage I-III colorectal cancer undergoing surgery, with or without neoadjuvant and/or adjuvant treatment.
Patients were followed up using computed tomography and CEA at intervals of 1 and 3 years.
Longitudinal ctDNA testing was performed using the Pathlight assay before and after surgical interventions.
532 patients were enrolled, with 494 having pathologic stage I-III colorectal cancer.
Ultrasensitive ctDNA detection showed a baseline detection rate of 92% among treatment-naive patients.
The primary endpoint associated ctDNA status with recurrence-free interval, while secondary endpoints evaluated its clinical performance.

No takes yet. Share an insight, caveat, or question.

Observational study shows ctDNA detects MRD in colorectal cancer, suggesting improvements in treatment strategies.

Merk et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark